ICE v1.0

• Research type

  Research Study

• Full title

  A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer

• IRAS ID

  59078

• Contact name

  Christian Ottensmeier

• Eudract number

  2010-021863-34

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Small cell lung cancer (SCLC) is often sensitive to chemotherapy with good initial responses, but in advanced disease recurrence is inevitable. Some patients with SCLC develop activation of their immune system in response to the cancer. These patients tend to have better outcomes from the cancer suggesting immune targeted therapy may be a promising treatment approach. Ipilimumab is an antibody therapy which causes activation of the immune system. We wish to investigate whether addition of ipilimumab to standard chemotherapy is able to improve the survival of patients with advanced small cell lung cancer. Patients with advanced SCLC will receive 6 treatments with standard chemotherapy every 3 weeks. Ipilimumab will be added to treatments 3-6 and then continued every 12 weeks for as long as the patient continues to benefit from the treatment. The study will be run in 5 UK cancer centres and is expected to take 3 years to complete.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  10/H0502/95

• Date of REC Opinion

  17 Jan 2011

• REC opinion

  Favourable Opinion